Current State of Immunotherapy for Treatment of Glioblastoma

Current Treatment Options in Oncology
Tresa McGranahanSeema Nagpal

Abstract

At this time, there are no FDA-approved immune therapies for glioblastoma (GBM) despite many unique therapies currently in clinical trials. GBM is a highly immunosuppressive tumor and there are limitations to a safe immune response in the central nervous system. To date, there have been several failures of phase 3 immune therapy clinical trials in GBM. These trials have targeted single components of an antitumor immune response. Learning from these failures, the future of immunotherapy for GBM appears most hopeful for combination of immune therapies to overcome the profound immunosuppression of this disease. Understanding biomarkers for appropriate patient selection as well as tumor progression are necessary for implementation of immunotherapy for GBM.

References

Jan 27, 2005·Journal of Cancer Research and Clinical Oncology·R MartinezG Schackert
Jan 27, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jian Gang ZhangMartin R Jadus
Jan 14, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nabil AhmedStephen Gottschalk
Mar 13, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christine E BrownMichael C Jensen
Feb 27, 2013·Cancer Research·Yuhui HuangRakesh K Jain
Apr 12, 2014·Neuro-oncology·Bart ThaciSadhak Sengupta
May 20, 2014·Cancer Immunology Research·F Stephen HodiDavid McDermott
Jun 14, 2014·Science·Anoop P PatelBradley E Bernstein
Oct 31, 2014·Neuro-oncology·Anna Sophie BerghoffWolfgang Wick
Jun 11, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christine E BrownMichael C Jensen
Aug 12, 2015·Nature Reviews. Neurology·Matthias PreusserJohn H Sampson
Sep 2, 2015·Neuro-oncology·Edjah K NduomAmy B Heimberger
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Nov 8, 2015·The Lancet Oncology·Hideho OkadaDavid A Reardon
Dec 8, 2015·Journal of the National Cancer Institute·Congcong ZhangWinfried S Wels
Mar 30, 2016·Brain : a Journal of Neurology·Kenneth L PitterDolores Hambardzumyan
Aug 9, 2016·Expert Review of Vaccines·Teilo H Schaller, John H Sampson
Dec 29, 2016·The New England Journal of Medicine·Christine E BrownBehnam Badie
Jan 9, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S CuzzubboA F Carpentier
Feb 15, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Orin BlochAndrew T Parsa
May 23, 2017·Therapeutic Advances in Medical Oncology·Tresa McGranahanSeema Nagpal
Jun 20, 2017·Case Reports in Oncology·Stephanie SchneiderSteffen Böhm
Jun 24, 2017·Translational Research : the Journal of Laboratory and Clinical Medicine·David Chen, James Yang
Jul 2, 2017·Journal of Neuro-oncology·Abdulrazag AjlanLawrence Recht
Aug 2, 2017·Translational Research : the Journal of Laboratory and Clinical Medicine·Analiz RodriguezBehnam Badie
Aug 9, 2017·Current Treatment Options in Oncology·Russell MaxwellMichael Lim
Aug 25, 2017·Molecular Cancer Therapeutics·Aaron M GoodmanRazelle Kurzrock
Sep 20, 2017·Nature Reviews. Clinical Oncology·Sattva S NeelapuElizabeth J Shpall
Dec 12, 2017·The New England Journal of Medicine·Sattva S NeelapuWilliam Y Go
Dec 20, 2017·Journal for Immunotherapy of Cancer·Samantha N ReissChristian Grommes
Mar 7, 2018·Neuro-oncology·Stephen J BagleyDonald M O'Rourke
Apr 10, 2018·Immunity·Vésteinn ThorssonIlya Shmulevich

❮ Previous
Next ❯

Citations

May 23, 2020·Journal of Cellular and Molecular Medicine·Yingxiao CaoYanhui Qi
May 14, 2020·Expert Opinion on Investigational Drugs·Maria B Garcia-FabianiMaria G Castro
Jun 10, 2020·Biomedicines·Verena J HerbenerHannah Strobel
Jul 29, 2020·Current Nutrition Reports·Jonathan G Thomas, Erol Veznedaroglu
Aug 20, 2019·BMC Cancer·Xiaozhi Li, Yutong Meng
Aug 9, 2020·Frontiers in Immunology·Syreeta DeCordovaUday Kishore
Oct 6, 2020·Neuro-oncology Practice·Megan L MontoyaHideho Okada
Jul 31, 2019·Nature Immunology·Christopher M JacksonMichael Lim
Jul 15, 2020·Cancer Immunology, Immunotherapy : CII·John W RutlandMary Fowkes
Jul 30, 2020·Current Treatment Options in Oncology·Nicholas P Tschernia, Simon Khagi
Apr 16, 2020·Cancers·Vilashini RajaratnamShama Parveen Mirza
Apr 3, 2020·Expert Review of Vaccines·Vaishali Y Londhe, Varada Date
Jan 22, 2020·Expert Opinion on Biological Therapy·David B AltshulerMaria G Castro
May 16, 2020·Cellular and Molecular Neurobiology·Pengfei XiaYimin Huang
Jun 5, 2020·Journal of Molecular Neuroscience : MN·Weihai NingHongwei Zhang
Oct 18, 2020·International Journal of Molecular Sciences·Sergio Rius-RocabertEstanislao Nistal-Villan
Oct 14, 2020·Cell Biology International·S Daisy PrecillaAnitha Thirugnanasambandhar Sivasubramanian
Nov 21, 2020·Immunology and Cell Biology·Laverne D RobilliardE Scott Graham
Jan 20, 2021·The International Journal of Neuroscience·Peng WangWang Xi
Nov 13, 2020·Frontiers in Immunology·Joshua R D PearsonStephanie E B McArdle
Dec 18, 2020·Frontiers in Immunology·Na ZhangHua You
Jan 5, 2021·Neuro-oncology Advances·Tiffany G BakerDavid M Meredith
Feb 13, 2021·Cancer Cell·Liang-Bo WangUNKNOWN Clinical Proteomic Tumor Analysis Consortium
Dec 1, 2020·Toxicology Reports·Athina-Maria AloizouEfthimios Dardiotis
Feb 25, 2021·Advanced Nanobiomed Research·Nerea Iturrioz-RodríguezGianni Ciofani
Mar 6, 2021·Frontiers in Molecular Biosciences·Xiaomeng LiShuo Xu
Mar 16, 2021·Frontiers in Oncology·Keenan PiperCharles Cobbs
Sep 9, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Gi Doo ChaDae-Hyeong Kim
Feb 6, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Balint OtvosJustin D Lathia
Apr 17, 2021·Frontiers in Oncology·Sheng Wang, Xia Xu
Apr 20, 2021·Frontiers in Cell and Developmental Biology·Hongtao ZhuKai Shu

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT03405792
NCT02311920
NCT02658981
NCT02335918
NCT03058289
NCT02327078
NCT02794883
NCT03018288
NCT02529072
NCT03014804

Software Mentioned

Celldex
ASPECT

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Related Papers

Journal of Immunology Research
Linda W XuGordon Li
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
C AngP Kavan
© 2022 Meta ULC. All rights reserved